Semaglutide

5mg/vial · GLP-1 Agonist

About this peptide

Semaglutide is a GLP-1 receptor agonist with the most extensive clinical track record in its class. The STEP trials demonstrated 15–17% mean body weight reduction at 68 weeks across thousands of participants. Marketed as Ozempic for type 2 diabetes and Wegovy for weight management, it is the gold-standard reference peptide for GLP-1 receptor research.